Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL232773 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL15635357 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL338160 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL232777 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL5908851 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL855765 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL1172967 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL416739 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL509143 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Cyclohexane SCHEMBL7396484 | 1.00 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2018-10-25 | — | — | US | disclosed |
| CN-104211624-B | For the pleuromutilin derivative for the disease for treating microbe-mediated | 纳布里瓦治疗股份公司 | 2017-12-15 | — | — | CN | disclosed |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-2929883-A1 | Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors | INSTITUT PASTEUR (FR) | 2015-10-14 | — | — | EP | disclosed |
| CN-104211624-A | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG | 2014-12-17 | — | — | CN | disclosed |
| US-20120029072-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG | 2012-02-02 | — | — | US | disclosed |
| US-8071643-B2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2011-12-06 | — | — | US | disclosed |
| CN-1930180-B | L-saccharide glucose lipid A analogue | SANKYO CO | 2010-05-26 | — | — | CN | disclosed |
| CN-101668738-A | Pleuromutilin derivatives for the treatment of microbial mediated diseases | NABRIVA THERAPEUTICS AG | 2010-03-10 | — | — | CN | disclosed |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2010-02-11 | — | — | US | disclosed |
| US-20090118366-A1 | ORGANIC COMPOUNDS | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2009-05-07 | — | — | US | disclosed |
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
| CN-1930180-A | L-saccharide glucose lipid a analogue | SANKYO CO (JP) | 2007-03-14 | — | — | CN | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 870/4885LMNA 4302/4885HSD17B10 2438/4885 |
| US-20090118366-A1 | ORGANIC COMPOUNDS | C5, C9, C1S | ALDH1A1 553/4885LMNA 3077/4885HSD17B10 329/4885 |
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 852/4885LMNA 4184/4885HSD17B10 2454/4885 |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 870/4885LMNA 4302/4885HSD17B10 2438/4885 |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | ALDH1A1 1122/4885LMNA 4468/4885HSD17B10 2577/4885 |
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | ALDH1A1 1640/4885LMNA 1907/4885HSD17B10 141/4885 |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, ALPI | ALDH1A1 1565/4885LMNA 4358/4885HSD17B10 2154/4885 |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | ALDH1A1 1122/4885LMNA 4468/4885HSD17B10 2577/4885 |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | ALDH1A1 3830/4885LMNA 3096/4885HSD17B10 3847/4885 |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 852/4885LMNA 4184/4885HSD17B10 2454/4885 |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | ALDH1A1 870/4885LMNA 4302/4885HSD17B10 2438/4885 |
| US-20120029072-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, PLEC | ALDH1A1 654/4885LMNA 4210/4885HSD17B10 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.